Halozyme Therapeutics stock hits all-time high at 77.6 USD

Halozyme Therapeutics Inc. stock reached an all-time high of 77.6 USD, marking a significant milestone for the biotechnology company. According to InvestingPro, the company boasts a perfect Piotroski Score of 9, indicating exceptional financial strength, while maintaining robust financials with a healthy current ratio of 8.36. Over the past year, the stock has experienced a robust increase, with a 1-year change of 29.69%. The company’s impressive YTD return of 60.38% and strong revenue growth of 35% demonstrate solid operational execution. This upward trajectory reflects strong investor confidence and positive market sentiment towards the company’s innovative therapeutic solutions. The achievement of an all-time high underscores Halozyme’s strategic advancements and successful execution of its business model, positioning it favorably in the competitive biotech industry. InvestingPro analysis suggests the stock may have additional upside potential, with 7 analysts recently revising their earnings estimates upward. Discover more insights with InvestingPro’s comprehensive research report.

In other recent news, Halozyme Therapeutics reported its Q2 2025 earnings, revealing a mixed performance. The company achieved an earnings per share (EPS) of $1.54, which exceeded analyst expectations of $1.24 by 24.19%. However, revenue was significantly lower than anticipated, coming in at $206 million compared to the expected $286.01 million, a shortfall of 27.97%. Following the earnings report, Citizens JMP raised its price target for Halozyme to $91.00 from $78.00, maintaining a Market Outperform rating, citing the company’s strong financial results and increased guidance for 2025.

Morgan Stanley upgraded Halozyme from Equalweight to Overweight, increasing its price target to $75.00 from $62.00. This upgrade was influenced by the passage of the One Big Beautiful Bill, which includes the ORPHAN Cures Act, potentially benefiting Halozyme. Goldman Sachs also adjusted its price target on Halozyme to $56.00 from $55.00, maintaining a Neutral rating. This change follows their analysis of the anticipated effects of the upcoming Centers for Medicare & Medicaid Services guidance on the Inflation Reduction Act for Part B drugs, a factor contributing to investor uncertainty. These developments highlight the varied analyst perspectives on Halozyme’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.